| Presented by: | The Cleveland Clinic Foundation Center for Continuing Education |
| Lecturer | Leonard Calabrese, DO, Mark Genovese, MD, Edward Keystone, MD, FRCPC, Scott Plevy, MD, Josef Smolen, MD and E. William St. Clair, MD |
| Approximate duration: | 2.5 hrs. |
| Summary points: | This audiovisual CME programme includes findings from the Biologics Therapies Summitt III, in which a panel of rheumatology experts describe the new approaches for targeting B cells for the treatment of autoimmune diseases, and review the potential efficacy and safety ramifications of intra-cellular enzyme inhibition. |
| Accreditation: | The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credits.
Expiration Date: September 4, 2011. |
| Other: | |
E-Mail this webcast/CME to a colleague
Biologic Therapies III The New Agents
Go to webcast/CME
E-Mail this webcast/CME to a colleague
Remind me of this
